Patents by Inventor Ramzi Sweis

Ramzi Sweis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NAMPT and ROCK inhibitors
    Patent number: 10093624
    Abstract: Disclosed are isoindoline carboxamide, dihydropyrrolopyridine carboxamide, and dihydropyrrolopyrimidine carboxamide compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are isoindoline carboxamide, dihydropyrrolopyridine carboxamide, and dihydropyrrolopyrimidine carboxamide compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of treating diseases during which ROCK is expressed.
    Type: Grant
    Filed: October 12, 2015
    Date of Patent: October 9, 2018
    Assignee: AbbVie Inc.
    Inventors: Rick F. Clark, Michael L. Curtain, Todd M. Hansen, Howard R. Heyman, Helmut Mack, Michael Michaelides, Marina A. Pliushchev, Omar J. Shah, Bryan K. Sorensen, Ramzi Sweis, Chris Tse, Anil Vasudevan, Kevin R. Woller
  • Substituted indoles
    Patent number: 9932340
    Abstract: The invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by SUV420H1. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: April 3, 2018
    Assignee: AbbVie Inc.
    Inventors: Yujia Dai, William McClellan, Mike Michaelides, Ramzi Sweis, Noel Wilson, Justin Dietrich
  • Substituted Indoles
    Publication number: 20170349589
    Abstract: The invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by SUV420H1. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Application
    Filed: December 17, 2015
    Publication date: December 7, 2017
    Applicant: AbbVie Inc.
    Inventors: Yujia Dai, William McClellan, Mike Michaelides, Ramzi Sweis, Noel Wilson, Justin Dietrich
  • Substituted Indoles
    Publication number: 20170174688
    Abstract: The invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by SUV420H1. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Application
    Filed: December 17, 2015
    Publication date: June 22, 2017
    Applicant: AbbVie Inc.
    Inventors: Yujia Dai, William McClellan, Mike Michaelides, Ramzi Sweis, Noel Wilson, Justin Dietrich
  • NAMPT INHIBITORS
    Publication number: 20170135994
    Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
    Type: Application
    Filed: October 8, 2015
    Publication date: May 18, 2017
    Applicant: AbbVie Inc.
    Inventors: Richard F. Clark, Bryan Sorensen, Augustine T. Osuma, Robin Frey, Kenton Longenecker, George Doherty, Michael L. Curtin, Michael Michaelides, Ramzi Sweis, Marina Pliushchev, Andrew Judd, Todd Hansen, Howard R. Heyman
  • NAMPT INHIBITORS
    Publication number: 20160184282
    Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
    Type: Application
    Filed: October 8, 2015
    Publication date: June 30, 2016
    Applicant: AbbVie Inc.
    Inventors: Richard F. Clark, Bryan Sorensen, Augustine T. Osuma, Robin Frey, Kenton Longenecker, George Doherty, Michael L. Curtin, Michael Michaelides, Ramzi Sweis, Marina Pliushchev, Andrew Judd, Todd Hansen, Howard R. Heyman
  • NAMPT INHIBITORS
    Publication number: 20160184281
    Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
    Type: Application
    Filed: October 8, 2015
    Publication date: June 30, 2016
    Applicant: ABBVIE INC.
    Inventors: Richard F. Clark, Bryan Sorensen, Augustine T. Osuma, Robin Frey, Kenton Longenecker, George Doherty, Michael L. Curtin, Michael Michaelides, Ramzi Sweis, Marina Pliushchev, Andrew Judd, Todd Hansen, Howard R. Heyman
  • NAMPT and rock inhibitors
    Patent number: 9302989
    Abstract: Disclosed are 1,3-dihydro-2H-isoindole compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of using the compounds to treat diseases during which NAMPT is expressed, e.g., cancer, metabolic disorders, and inflammatory disorders. Disclosed are 1,3-dihydro-2H-isoindole compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of using the compounds to treat diseases during which ROCK is expressed, e.g., cancer, cardiovascular disorders, and inflammatory disorders.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: April 5, 2016
    Assignee: AbbVie Inc.
    Inventors: Michael L. Curtin, Bryan K. Sorensen, Howard R. Heyman, Richard F. Clark, Kevin R. Woller, Omar J. Shah, Michael Michaelides, Chris Tse, Anil Vasudevan, Helmut Mack, Todd M. Hansen, Ramzi Sweis, Marina A. Pliushchev
  • Nampt and Rock Inhibitors
    Publication number: 20160031880
    Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of treating diseases during which ROCK is expressed.
    Type: Application
    Filed: October 12, 2015
    Publication date: February 4, 2016
    Applicant: ABBVIE INC.
    Inventors: Rick F. Clark, Michael L. Curtain, Todd M. Hansen, Howard R. Heyman, Helmut Mack, Michael Michaelides, Marina A. Pliushchev, Omar J. Shah, Bryan K. Sorensen, Ramzi Sweis, Chris Tse, Anil Vasudevan, Kevin R. Woller
  • Cyclic amine substituted oxazolidinone CETP inhibitor
    Patent number: 9221834
    Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compound of Formula I, A3 is a substituted phenyl group or indanyl group. Formula (I).
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: December 29, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Zhijian Lu, Yi-Heng Chen, Cameron Smith, Hong Li, Christopher F. Thompson, Julianne Hunt, Florida Kallashi, Ramzi Sweis, Peter Sinclair, Samantha E. Adamson, Guizhen Dong, Debra L. Ondeyka, Xiaoxia Qian, Wanying Sun, Petr Vachal, Kake Zhao
  • Cyclic Amine Substituted Oxazolidinone CETP Inhibitor
    Publication number: 20130331372
    Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compound of Formula I, A3 is a substituted phenyl group or indanyl group. Formula (I).
    Type: Application
    Filed: October 25, 2011
    Publication date: December 12, 2013
    Inventors: Zhijian Lu, Yi-Heng Chen, Cameron Smith, Hong Li, Christopher F. Thompson, Julianne Hunt, Florida Kallashi, Ramzi Sweis, Peter Sinclair, Samantha E. Adamson, Guizhen Dong, Debra L. Ondeyka, Xiaoxia Qian, Wanying Sun, Petr Vachal, Kake Zhao
  • NAMPT AND ROCK INHIBITORS
    Publication number: 20120122842
    Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of treating diseases during which ROCK is expressed.
    Type: Application
    Filed: November 11, 2011
    Publication date: May 17, 2012
    Applicant: Abbott Laboratories
    Inventors: Michael L. Curtin, Bryan K. Sorensen, Howard R. Heyman, Richard F. Clark, Kevin R. Woller, Omar J. Shah, Michael Michaelides, Chris Tse, Anil Vasudevan, Helmut Mack, Todd M. Hansen, Ramzi Sweis, Marina A. Pliushchev